Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.58
NAS:BIIB's Cash to Debt is ranked lower than
86% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:BIIB: 0.58 )
Ranked among companies with meaningful Cash to Debt only.
NAS:BIIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.49 Max: 28.5
Current: 0.58
0.25
28.5
Equity to Asset 0.53
NAS:BIIB's Equity to Asset is ranked lower than
67% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:BIIB: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
NAS:BIIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 0.84
Current: 0.53
0.48
0.84
Interest Coverage 25.35
NAS:BIIB's Interest Coverage is ranked lower than
80% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:BIIB: 25.35 )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.25  Med: 50.39 Max: 488.91
Current: 25.35
19.25
488.91
F-Score: 5
Z-Score: 6.61
M-Score: -2.86
WACC vs ROIC
4.50%
32.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 47.86
NAS:BIIB's Operating margin (%) is ranked higher than
96% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:BIIB: 47.86 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:BIIB' s Operating margin (%) Range Over the Past 10 Years
Min: 16.4  Med: 31.21 Max: 47.86
Current: 47.86
16.4
47.86
Net-margin (%) 33.97
NAS:BIIB's Net-margin (%) is ranked higher than
94% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:BIIB: 33.97 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:BIIB' s Net-margin (%) Range Over the Past 10 Years
Min: 8.11  Med: 23.31 Max: 33.97
Current: 33.97
8.11
33.97
ROE (%) 35.19
NAS:BIIB's ROE (%) is ranked higher than
97% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:BIIB: 35.19 )
Ranked among companies with meaningful ROE (%) only.
NAS:BIIB' s ROE (%) Range Over the Past 10 Years
Min: 3.09  Med: 18.97 Max: 35.19
Current: 35.19
3.09
35.19
ROA (%) 19.25
NAS:BIIB's ROA (%) is ranked higher than
96% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:BIIB: 19.25 )
Ranked among companies with meaningful ROA (%) only.
NAS:BIIB' s ROA (%) Range Over the Past 10 Years
Min: 2.57  Med: 13.24 Max: 22.42
Current: 19.25
2.57
22.42
ROC (Joel Greenblatt) (%) 181.90
NAS:BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:BIIB: 181.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:BIIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 34.41  Med: 77.96 Max: 189.7
Current: 181.9
34.41
189.7
Revenue Growth (3Y)(%) 26.50
NAS:BIIB's Revenue Growth (3Y)(%) is ranked higher than
79% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:BIIB: 26.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:BIIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.9  Med: 24.8 Max: 78.2
Current: 26.5
-1.9
78.2
EBITDA Growth (3Y)(%) 35.90
NAS:BIIB's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:BIIB: 35.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:BIIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.6  Med: 31.8 Max: 82.3
Current: 35.9
-18.6
82.3
EPS Growth (3Y)(%) 38.60
NAS:BIIB's EPS Growth (3Y)(%) is ranked higher than
86% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:BIIB: 38.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:BIIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66  Med: 34.9 Max: 205.2
Current: 38.6
-66
205.2
» NAS:BIIB's 10-Y Financials

Financials (Next Earnings Date: 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BIIB Guru Trades in Q3 2015

Steven Cohen 6,800 sh (New)
Joel Greenblatt 9,410 sh (New)
John Burbank 10,551 sh (New)
Ray Dalio 14,766 sh (New)
Richard Snow 45,861 sh (+336.77%)
Vanguard Health Care Fund 3,666,723 sh (+105.96%)
Signature Select Canadian Fund 7,900 sh (+43.64%)
Ken Fisher 112,448 sh (+38.94%)
Ron Baron 11,814 sh (+29.20%)
Mario Gabelli 4,797 sh (unchged)
Mairs and Power 1,095 sh (unchged)
Pioneer Investments Sold Out
Andreas Halvorsen Sold Out
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 15,843,460 sh (-3.99%)
Murray Stahl 7,713 sh (-7.44%)
Frank Sands 4,121,400 sh (-12.92%)
Jeremy Grantham 179,221 sh (-28.61%)
Jim Simons 34,961 sh (-66.79%)
» More
Q4 2015

BIIB Guru Trades in Q4 2015

Andreas Halvorsen 368,864 sh (New)
First Eagle Investment 193,885 sh (New)
John Buckingham 17,389 sh (New)
Jeff Auxier 7,195 sh (New)
Paul Tudor Jones 4,368 sh (New)
John Paulson 36,200 sh (New)
Steven Cohen 86,700 sh (+1175.00%)
Joel Greenblatt 84,577 sh (+798.80%)
Ray Dalio 25,106 sh (+70.03%)
Vanguard Health Care Fund 3,810,023 sh (+3.91%)
Mario Gabelli 4,805 sh (+0.17%)
Mairs and Power 1,095 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Murray Stahl 7,705 sh (-0.10%)
PRIMECAP Management 15,810,625 sh (-0.21%)
Ken Fisher 110,475 sh (-1.75%)
Richard Snow 40,290 sh (-12.15%)
Ron Baron 10,240 sh (-13.32%)
Frank Sands 3,367,531 sh (-18.29%)
Jeremy Grantham 98,334 sh (-45.13%)
» More
Q1 2016

BIIB Guru Trades in Q1 2016

Pioneer Investments 880 sh (New)
Lee Ainslie 9,370 sh (New)
Jim Simons 127,661 sh (New)
Ronald Muhlenkamp 23,853 sh (New)
Joel Greenblatt 298,673 sh (+253.14%)
John Paulson 118,400 sh (+227.07%)
Richard Snow 91,801 sh (+127.85%)
Ron Baron 16,047 sh (+56.71%)
Jeff Auxier 9,015 sh (+25.30%)
Steven Cohen 102,200 sh (+17.88%)
First Eagle Investment 224,585 sh (+15.83%)
PRIMECAP Management 16,246,726 sh (+2.76%)
Mario Gabelli 4,810 sh (+0.10%)
Vanguard Health Care Fund 3,810,023 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Signature Select Canadian Fund Sold Out
John Buckingham 16,809 sh (-3.34%)
Mairs and Power 1,025 sh (-6.39%)
Frank Sands 3,141,109 sh (-6.72%)
Ray Dalio 23,106 sh (-7.97%)
Ken Fisher 90,405 sh (-18.17%)
Andreas Halvorsen 230,947 sh (-37.39%)
Paul Tudor Jones 1,000 sh (-77.11%)
Jeremy Grantham 1,380 sh (-98.60%)
» More
Q2 2016

BIIB Guru Trades in Q2 2016

HOTCHKIS & WILEY 229,000 sh (New)
David Dreman 150 sh (New)
Sarah Ketterer 489,263 sh (New)
Paul Tudor Jones 18,123 sh (+1712.30%)
Andreas Halvorsen 3,210,507 sh (+1290.15%)
Richard Snow 211,561 sh (+130.46%)
Ray Dalio 51,461 sh (+122.72%)
Jeff Auxier 17,985 sh (+99.50%)
First Eagle Investment 332,760 sh (+48.17%)
Pioneer Investments 1,099 sh (+24.89%)
Joel Greenblatt 368,095 sh (+23.24%)
Ron Baron 19,621 sh (+22.27%)
Lee Ainslie 11,010 sh (+17.50%)
Ken Fisher 101,919 sh (+12.74%)
John Paulson 123,100 sh (+3.97%)
Vanguard Health Care Fund 3,956,663 sh (+3.85%)
John Buckingham 16,831 sh (+0.13%)
Murray Stahl 7,705 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Steven Cohen Sold Out
Jeremy Grantham Sold Out
Mario Gabelli 4,797 sh (-0.27%)
Ronald Muhlenkamp 23,703 sh (-0.63%)
PRIMECAP Management 16,024,861 sh (-1.37%)
Frank Sands 2,970,230 sh (-5.44%)
Jim Simons 40,400 sh (-68.35%)
Samuel Isaly 176,000 sh (-12.00%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SHPG, NAS:CELG, NAS:REGN, OTCPK:CSLLY, NAS:GILD, NAS:ALXN, OTCPK:NVZMY, NAS:VRTX, NYSE:NVO, OTCPK:ALIOY, NAS:INCY, NAS:BMRN, OTCPK:UCBJF, NAS:MDVN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:ALNY, NAS:AMGN » details
Traded in other countries:BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.

Biogen Inc was founded in 1978 in the state if Delaware. In March 2015, its name changed from Biogen Idec Inc. to Biogen Inc. It is a biotechnology company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.

Ratios

vs
industry
vs
history
P/E(ttm) 17.87
BIIB's P/E(ttm) is ranked higher than
70% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. BIIB: 17.87 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s P/E(ttm) Range Over the Past 10 Years
Min: 11.73  Med: 26.18 Max: 477.1
Current: 17.87
11.73
477.1
Forward P/E 14.97
BIIB's Forward P/E is ranked higher than
61% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. BIIB: 14.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.87
BIIB's PE(NRI) is ranked higher than
72% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 17.87 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s PE(NRI) Range Over the Past 10 Years
Min: 11.73  Med: 26.18 Max: 530.11
Current: 17.87
11.73
530.11
Price/Owner Earnings (ttm) 25.16
BIIB's Price/Owner Earnings (ttm) is ranked higher than
58% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. BIIB: 25.16 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIIB' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.81  Med: 25.98 Max: 168.8
Current: 25.16
10.81
168.8
P/B 5.92
BIIB's P/B is ranked lower than
68% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. BIIB: 5.92 )
Ranked among companies with meaningful P/B only.
BIIB' s P/B Range Over the Past 10 Years
Min: 1.86  Med: 4.02 Max: 9.6
Current: 5.92
1.86
9.6
P/S 6.14
BIIB's P/S is ranked higher than
67% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. BIIB: 6.14 )
Ranked among companies with meaningful P/S only.
BIIB' s P/S Range Over the Past 10 Years
Min: 2.81  Med: 6.06 Max: 11.94
Current: 6.14
2.81
11.94
PFCF 21.39
BIIB's PFCF is ranked higher than
62% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. BIIB: 21.39 )
Ranked among companies with meaningful PFCF only.
BIIB' s PFCF Range Over the Past 10 Years
Min: 10.16  Med: 21.57 Max: 39.29
Current: 21.39
10.16
39.29
POCF 17.73
BIIB's POCF is ranked higher than
58% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. BIIB: 17.73 )
Ranked among companies with meaningful POCF only.
BIIB' s POCF Range Over the Past 10 Years
Min: 7.95  Med: 18.01 Max: 35.29
Current: 17.73
7.95
35.29
EV-to-EBIT 12.96
BIIB's EV-to-EBIT is ranked higher than
70% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. BIIB: 12.96 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 18.6 Max: 68.3
Current: 12.96
8.1
68.3
EV-to-EBITDA 11.61
BIIB's EV-to-EBITDA is ranked higher than
69% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BIIB: 11.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 14.4 Max: 27
Current: 11.61
6.6
27
PEG 0.59
BIIB's PEG is ranked higher than
86% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.18 vs. BIIB: 0.59 )
Ranked among companies with meaningful PEG only.
BIIB' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 0.98 Max: 48.49
Current: 0.59
0.34
48.49
Shiller P/E 43.05
BIIB's Shiller P/E is ranked higher than
57% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. BIIB: 43.05 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s Shiller P/E Range Over the Past 10 Years
Min: 32.21  Med: 85.11 Max: 1287.75
Current: 43.05
32.21
1287.75
Current Ratio 2.96
BIIB's Current Ratio is ranked lower than
64% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. BIIB: 2.96 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.29 Max: 17.39
Current: 2.96
0.78
17.39
Quick Ratio 2.56
BIIB's Quick Ratio is ranked lower than
64% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. BIIB: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.89 Max: 16.79
Current: 2.56
0.7
16.79
Days Inventory 255.56
BIIB's Days Inventory is ranked lower than
80% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. BIIB: 255.56 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 255.56
219.47
266.3
Days Sales Outstanding 41.99
BIIB's Days Sales Outstanding is ranked higher than
67% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. BIIB: 41.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 44.3 Max: 48.62
Current: 41.99
39.79
48.62
Days Payable 62.22
BIIB's Days Payable is ranked higher than
54% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. BIIB: 62.22 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 62.22  Med: 105.99 Max: 148.21
Current: 62.22
62.22
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.60
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. BIIB: 2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -31  Med: 4.9 Max: 30.9
Current: 2.6
-31
30.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.70
BIIB's Price/Tangible Book is ranked lower than
85% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. BIIB: 15.70 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 6.34 Max: 26.82
Current: 15.7
0.91
26.82
Price/Projected FCF 1.95
BIIB's Price/Projected FCF is ranked higher than
69% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. BIIB: 1.95 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 2.1 Max: 25.99
Current: 1.95
0.65
25.99
Price/DCF (Earnings Based) 0.63
BIIB's Price/DCF (Earnings Based) is ranked higher than
85% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 1.06 vs. BIIB: 0.63 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.01
BIIB's Price/Median PS Value is ranked lower than
51% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. BIIB: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.99 Max: 6.96
Current: 1.01
0.23
6.96
Price/Peter Lynch Fair Value 0.71
BIIB's Price/Peter Lynch Fair Value is ranked higher than
84% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. BIIB: 0.71 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.41 Max: 20.5
Current: 0.71
0.44
20.5
Price/Graham Number 3.53
BIIB's Price/Graham Number is ranked lower than
58% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. BIIB: 3.53 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.6  Med: 3.28 Max: 36.53
Current: 3.53
0.6
36.53
Earnings Yield (Greenblatt) (%) 7.78
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. BIIB: 7.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 5.4 Max: 12.3
Current: 7.78
1.5
12.3
Forward Rate of Return (Yacktman) (%) 33.65
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
79% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. BIIB: 33.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -4.6  Med: 25.8 Max: 45.3
Current: 33.65
-4.6
45.3

More Statistics

Revenue (TTM) (Mil) $11,238
EPS (TTM) $ 17.14
Beta0.40
Short Percentage of Float1.06%
52-Week Range $223.02 - 333.65
Shares Outstanding (Mil)219.12

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 11,456 11,632 12,660 14,195
EPS ($) 19.20 20.38 22.66 24.79
EPS w/o NRI ($) 19.20 20.38 22.66 24.79
EPS Growth Rate
(3Y to 5Y Estimate)
8.28%
Dividends Per Share ($)
» More Articles for NAS:BIIB

Headlines

Articles On GuruFocus.com
Sarah Ketterer Takes 3 Positions in 2nd Quarter Aug 15 2016 
Richard Snow Slashed Abercrombie & Fitch Stake in 2nd Quarter Aug 12 2016 
Jeff Auxier's Summer 2016 Market Commentary Aug 05 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
The Neglected Biogen Jun 13 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
High Quality Stocks Gurus Are Buying Jun 07 2016 
Joel Greenblatt Bets on eBay, Intel, Biogen Jun 03 2016 
Jeff Auxier's Spring 2016 Market Commentary May 20 2016 
Richard Snow Boosts Biogen, Keysight Technologies May 12 2016 

More From Other Websites
Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure Sep 29 2016
Anavex Jumps on Biogen Testing Deal (AVXL, BIIB) Sep 29 2016
Biogen Submits NDA for SMA Drug (BIIB, IONS) Sep 28 2016
Newbie Anavex Rockets On Testing Deal With IBD 50 Stock Biogen Sep 28 2016
Anavex Soars on Biogen Agreement Sep 28 2016
ETF’s with exposure to Biogen, Inc. : September 28, 2016 Sep 28 2016
Anavex Compound to be Tested in Biogen Neurological Protection Model Sep 28 2016
Ionis/Biogen Complete Nusinersen NDA Submission in U.S. Sep 27 2016
Short Sellers Increase Bets in Major Biotechs Sep 27 2016
Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for... Sep 26 2016
Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for... Sep 26 2016
Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for... Sep 26 2016
[$$] Rodin Therapeutics, a Neurology Drug Firm, Expands Management Team Sep 23 2016
Top 5 profitable Biotech stocks : September 23, 2016 Sep 23 2016
Biogen Bets on Nusinersen (BIIB, IONS) Sep 22 2016
Amazon (AMZN), Charter Communications (CHTR) And 3 Other Hot Stocks That Billionaire Ken Griffin Is... Sep 21 2016
Gilead Sciences: Allergan's Next Target? Sep 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)